logo

FDA Calendar

Share
Company Name Regeneron Pharmaceuticals
Drug Name Libtayo (sBLA)
Event Name FDA decision on Libtayo for patients with first-line locally advanced or metastatic non-small cell lung cancer with equal to or greater than 50% PD-L1 expression
Event Date 02/28/2021
Outcome Date
Outcome
Drug Status
Rival Drugs
Market Potential
Other Approvals Libtayo is already approved in the U.S. and European Union for adults with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation.
News
Return to FDA Calendar